These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35947606)

  • 1. A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike.
    Fu Y; da Fonseca Rezende E Mello J; Fleming BD; Renn A; Chen CZ; Hu X; Xu M; Gorshkov K; Hanson Q; Zheng W; Lee EM; Perera L; Petrovich R; Pradhan M; Eastman RT; Itkin Z; Stanley TB; Hsu A; Dandey V; Sharma K; Gillette W; Taylor T; Ramakrishnan N; Perkins S; Esposito D; Oh E; Susumu K; Wolak M; Ferrer M; Hall MD; Borgnia MJ; Simeonov A
    PLoS One; 2022; 17(8):e0272364. PubMed ID: 35947606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike.
    Fu Y; Rezende E Mello JDF; Fleming BD; Renn A; Chen CZ; Hu X; Xu M; Gorshkov K; Hanson Q; Zheng W; Lee EM; Perera L; Petrovich R; Pradhan M; Eastman RT; Itkin Z; Stanley T; Hsu A; Dandey V; Gillette W; Taylor T; Ramakrishnan N; Perkins S; Esposito D; Oh E; Susumu K; Wolak M; Ferrer M; Hall MD; Borgnia MJ; Simeonov A
    bioRxiv; 2022 Mar; ():. PubMed ID: 34729560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
    Huo J; Le Bas A; Ruza RR; Duyvesteyn HME; Mikolajek H; Malinauskas T; Tan TK; Rijal P; Dumoux M; Ward PN; Ren J; Zhou D; Harrison PJ; Weckener M; Clare DK; Vogirala VK; Radecke J; Moynié L; Zhao Y; Gilbert-Jaramillo J; Knight ML; Tree JA; Buttigieg KR; Coombes N; Elmore MJ; Carroll MW; Carrique L; Shah PNM; James W; Townsend AR; Stuart DI; Owens RJ; Naismith JH
    Nat Struct Mol Biol; 2020 Sep; 27(9):846-854. PubMed ID: 32661423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies.
    Wang WB; Liang Y; Jin YQ; Zhang J; Su JG; Li QM
    J Mol Graph Model; 2021 Dec; 109():108035. PubMed ID: 34562851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding Mechanism of Neutralizing Nanobodies Targeting SARS-CoV-2 Spike Glycoprotein.
    Golcuk M; Hacisuleyman A; Erman B; Yildiz A; Gur M
    J Chem Inf Model; 2021 Oct; 61(10):5152-5160. PubMed ID: 34581563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanobody engineering for SARS-CoV-2 neutralization and detection.
    Hannula L; Kuivanen S; Lasham J; Kant R; Kareinen L; Bogacheva M; Strandin T; Sironen T; Hepojoki J; Sharma V; Saviranta P; Kipar A; Vapalahti O; Huiskonen JT; Rissanen I
    Microbiol Spectr; 2024 Apr; 12(4):e0419922. PubMed ID: 38363137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern.
    Wu D; Cong J; Wei J; Hu J; Sun W; Ran W; Liao C; Zheng H; Ye L
    Int J Nanomedicine; 2023; 18():5781-5795. PubMed ID: 37869063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies.
    Kaewchim K; Glab-Ampai K; Mahasongkram K; Saenlom T; Thepsawat W; Chulanetra M; Choowongkomon K; Sookrung N; Chaicumpa W
    Viruses; 2023 May; 15(6):. PubMed ID: 37376552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-domain antibodies against SARS-CoV-2 RBD from a two-stage phage screening of universal and focused synthetic libraries.
    Chen F; Liu Z; Kang W; Jiang F; Yang X; Yin F; Zhou Z; Li Z
    BMC Infect Dis; 2024 Feb; 24(1):199. PubMed ID: 38350843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
    Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
    Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody.
    Valenzuela Nieto G; Jara R; Watterson D; Modhiran N; Amarilla AA; Himelreichs J; Khromykh AA; Salinas-Rebolledo C; Pinto T; Cheuquemilla Y; Margolles Y; López González Del Rey N; Miranda-Chacon Z; Cuevas A; Berking A; Deride C; González-Moraga S; Mancilla H; Maturana D; Langer A; Toledo JP; Müller A; Uberti B; Krall P; Ehrenfeld P; Blesa J; Chana-Cuevas P; Rehren G; Schwefel D; Fernandez LÁ; Rojas-Fernandez A
    Sci Rep; 2021 Feb; 11(1):3318. PubMed ID: 33558635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
    Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A
    J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529).
    Lu Y; Li Q; Fan H; Liao C; Zhang J; Hu H; Yi H; Peng Y; Lu J; Chen Z
    Int J Nanomedicine; 2023; 18():353-367. PubMed ID: 36700149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding.
    Yang J; Lin S; Sun H; Chen Z; Yang F; Lin X; Guo L; Wang L; Wen A; Zhang X; Dai Y; He B; Cao Y; Dong H; Liu X; Chen B; Li J; Zhao Q; Lu G
    Front Immunol; 2022; 13():820336. PubMed ID: 35663966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A SARS-CoV-2 nanobody that can bind to the RBD region may be used for treatment in COVID-19 in animals.
    Wu P; Yang Q; Zhao X; Liu Q; Xi J; Zhang F; He J; Yang H; Zhang C; Ma Z; Deng X; Wang Y; Chen C
    Res Vet Sci; 2022 Jul; 145():46-49. PubMed ID: 35152188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep mutational engineering of broadly-neutralizing nanobodies accommodating SARS-CoV-1 and 2 antigenic drift.
    Laroche A; Orsini Delgado ML; Chalopin B; Cuniasse P; Dubois S; Sierocki R; Gallais F; Debroas S; Bellanger L; Simon S; Maillère B; Nozach H
    MAbs; 2022; 14(1):2076775. PubMed ID: 35593235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.
    Pymm P; Adair A; Chan LJ; Cooney JP; Mordant FL; Allison CC; Lopez E; Haycroft ER; O'Neill MT; Tan LL; Dietrich MH; Drew D; Doerflinger M; Dengler MA; Scott NE; Wheatley AK; Gherardin NA; Venugopal H; Cromer D; Davenport MP; Pickering R; Godfrey DI; Purcell DFJ; Kent SJ; Chung AW; Subbarao K; Pellegrini M; Glukhova A; Tham WH
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33893175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants.
    He L; Wu Q; Zhang Z; Chen L; Yu K; Li L; Jia Q; Wang Y; Ni J; Wang C; Li Q; Zhai X; Zhao J; Liu Y; Fan R; Li YP
    Mol Pharm; 2024 Aug; 21(8):3866-3879. PubMed ID: 38920116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.